Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

August 11, 2017: By Jon Swedien
Bausch + Lomb Stellaris Elite

Bausch + Lomb Stellaris Elite

The Stellaris Elite platform builds on B+L’s Stellaris PC, a dual-function cataract/vitrectomy machine commercialized in 2010. The FDA gave the Stellaris Elite 501(k) clearance in May.

The new system features the ability to seamlessly integrate future technologies, such as the Vitesse hypersonic vitrectomy system, which will be exclusive to the Stellaris Elite, B+L said.

The Vitesse system is the first and only hypersonic, 100 percent open port vitrectomy platform, B+L said.

Stellaris Elite machines configured for retinal surgery will come equipped with the Vitesse technology, while the Vitesse hand-piece is slated to be released commercially in late 2017.

The Stellaris Elite offers a variety of vitrectomy cutters operating up to 7,500 cuts per minute (cpm), B+L said. The system will feature a new 27-gauge BiBlade vitrectomy cutter that offers cut rates up to 15 thousand cpm and features an open-port design resulting in a higher, more consistent flow rate than single port cutters, B+L said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022